Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-15), Japan Lifeline Co's Beta is -0.0540.
Japan Lifeline Co (TSE:7575) Beta Explanation
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
Japan Lifeline Co Beta Related Terms
Japan Lifeline Co Beta Historical Data
* Premium members only.
The historical data trend for Japan Lifeline Co's Beta can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Japan Lifeline Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Japan Lifeline Co Beta vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Japan Lifeline Co's Beta distribution charts can be found below:
* The bar in red indicates where Japan Lifeline Co's Beta falls into.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
Japan Lifeline Co (TSE:7575) has a Beta of -0.0540 as of Jul. 15, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Japan Lifeline Co and its competitors.
Is Japan Lifeline Co's Beta too high?
Japan Lifeline Co's current Beta is -0.0540. Overall, Japan Lifeline Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Japan Lifeline Co's Beta compare to ABT and SYK?
Japan Lifeline Co's Beta of -0.0540 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Japan Lifeline Co and its competitors. Japan Lifeline Co's current Beta is -0.0540. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Lifeline Co stock overvalued right now?
Based on GuruFocus' analysis, Japan Lifeline Co (TSE:7575) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,535.81, compared to a current price of 円1,374.00 — trading 10.5% below its estimated fair value. The current Beta is -0.0540. Japan Lifeline Co's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Japan Lifeline Co (TSE:7575), the current Beta is -0.0540 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Japan Lifeline Co (TSE:7575) Overvalued in 2026?
Based on GuruFocus' analysis, Japan Lifeline Co stock appears to be undervalued.
The current stock price of 円1,374.00 is trading 10.5% below its estimated GF Value™ of 円1,535.81.
GuruFocus considers Japan Lifeline Co to be Modestly Undervalued.
Key valuation signals for TSE:7575:
Beta: -0.0540
GF Value™: 円1,535.81 vs. price of 円1,374.00 (10.5% below fair value)
No single metric tells the full story. See the TSE:7575 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Japan Lifeline Co Ltd is a medical device company operating in Japan. It is engaged in the trading and manufacturing of medical devices specialized in the cardiovascular field. The company offers medical devices mainly for the treatment of cardiac and vascular diseases. It focuses on providing implantable devices to treat arrhythmias; disposable catheter devices with electrodes for diagnosis and treatment of arrhythmias; prosthetic devices to replace blood vessels and heart valves that lost their functions; and devices for intravascular treatment of cardiac infarction, arterial occlusions of the lower extremities and congenital cardiac diseases.
84GF Score
Get the complete analysis for TSE:7575
Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7575 has been successfully added to your 
